ArticleAnnals of surgical oncology2025
Activated Hippo Pathway is Associated with a Worse Response to Trastuzumab and Worse Survival in HER2-Positive Breast Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Neuron Projection Guidance Signature Associates with Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer.Annals of surgical oncology · 2026Article
- The Hippo signaling pathway in pediatric brain tumors: molecular mechanisms and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- Residual disease after neoadjuvant therapy in HER2-positive breast cancer: biology, burden, or both?Translational cancer research · 2026Article
- Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer.World journal of oncology · 2026Article
- Invasive Lobular Carcinoma Has Higher Immune Response Than Invasive Ductal Carcinoma in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers.World journal of oncology · 2025Article
- Intra-tumoral NK cells and their association with patient outcomes: a novel prognostic model incorporating NK cells and clinicopathologic features in gastric cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe Hippo signaling pathway is an evolutionarily conserved network that regulates cell proliferation, apoptosis, and stemness. It also plays an important role in tumorigenesis and cancer progression, and previous studies have indicated that Hippo signaling promotes trastuzumab resistance in breast cancer (BC). However, its clinical relevance in patients with BC remains unclear. PATIENTS AND
methodsClinical and transcriptomics data from two large cohorts, METABRIC and TCGA, were analyzed. A Hippo pathway score was calculated by applying Gene Set Variation Analysis to the curated Kyoto Encyclopedia of Genes and Genomes (KEGG) Hippo pathway gene set (43 genes). Patients were stratified into high and low groups based on the top tertile of Hippo pathway scores in each cohort.
resultsHigh Hippo pathway scores were significantly associated with worse disease-specific survival (DSS) in HER2-positive BC. In both cohorts, the Hippo pathway score showed the largest hazard ratio (HR) for DSS in HER2-positive BC compared with YAP1 or TAZ, transcription co-activators that are key components in the Hippo pathway (HR = 2.47, p = 0.04, and HR = 41.8, p = 0.03). Breast cancers with high Hippo pathway activity were associated with enrichment of cell proliferation and metastasis-related gene sets, including epithelial-mesenchymal transition, Notch, Hedgehog, and TGF-β signaling. Moreover, high Hippo pathway scores correlated with lower infiltration of anti-cancer immune cells (Th1 cells, dendritic cells, and M1-macrophages). Notably, low Hippo pathway scores were linked to a higher pathological complete response following trastuzumab-based neoadjuvant chemotherapy (p = 0.035).
conclusionsEnhanced Hippo pathway activity in HER2-positive BC is associated with worse prognoses, metastasis-related gene enrichment, and reduced anti-cancer immune cell infiltration, potentially contributing to trastuzumab resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.